TrialThe Journal of dermatology2019

Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study.

Ryosuke Mihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.